The Current State of Molecular Testing and Predictive Biomarkers in Gastrointestinal Malignancies

Not an official event of the 2020 Gastrointestinal (GI) Cancers Symposium. Not sponsored, endorsed, or accredited by any of the cosponsoring organizations of the 2020 GI Cancers Symposium.

Agenda

7:00 PM – 7:10 PM Welcome and Introduction

7:10 PM – 7:50 PM Histology-Agnostic Biomarkers in GI Malignancies

7:50 PM – 8:10 PM Biomarker-Driven Treatment of Advanced Colorectal Cancer

8:10 PM – 8:50 PM Biomarker-Driven Treatment of Advanced Non-CRC GI Malignancies

8:50 PM – 9:00 PM Panel Discussion and Audience Q&A

Faculty

Faculty
Pashtoon Kasi, MD, MS

Assistant Professor
Department of Oncology
University of Iowa
Iowa City, Iowa

Faculty
John L. Marshall, MD

Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Faculty
Michael Pishvaian, MD, PhD

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in biomarker testing to guide selection of individualized treatments for patients with gastrointestinal malignancies.

Target Audience 
This program is intended for medical oncologists, pathologists, and other healthcare providers involved in the management of patients with gastrointestinal malignancies.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply the available data and expert recommendations to determine which biomarkers should be tested in your patients with GI malignancies
  • Plan therapeutic strategies for patients with GI malignancies based on assessment of predictive biomarkers
  • Evaluate the clinical validity, utility, and differences among single biomarker companion diagnostics and available comprehensive genomic testing platforms using next-generation sequencing
  • Describe the applicability of genomic biomarkers beyond FDA-approved indications and utility of blood-based genomic testing modalities to guide treatment and disease monitoring as well as enrollment on clinical trials
  • Become familiar with the design of ongoing clinical trials for novel biomarker-driven treatment strategies in GI malignancies and counsel appropriate patients about availability and participation

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.